Survival following allogeneic transplant in patients with myelofibrosis
Standard
Survival following allogeneic transplant in patients with myelofibrosis. / Gowin, Krisstina; Ballen, Karen; Ahn, Kwang Woo; Hu, Zhen-Huan; Ali, Haris; Arcasoy, Murat O; Devlin, Rebecca; Coakley, Maria; Gerds, Aaron T; Green, Michael; Gupta, Vikas; Hobbs, Gabriela; Jain, Tania; Kandarpa, Malathi; Komrokji, Rami; Kuykendall, Andrew T; Luber, Kierstin; Masarova, Lucia; Michaelis, Laura C; Patches, Sarah; Pariser, Ashley C; Rampal, Raajit; Stein, Brady; Talpaz, Moshe; Verstovsek, Srdan; Wadleigh, Martha; Agrawal, Vaibhav; Aljurf, Mahmoud; Angel Diaz, Miguel; Avalos, Belinda R; Bacher, Ulrike; Bashey, Asad; Beitinjaneh, Amer M; Cerny, Jan; Chhabra, Saurabh; Copelan, Edward; Cutler, Corey S; DeFilipp, Zachariah; Gadalla, Shahinaz M; Ganguly, Siddhartha; Grunwald, Michael R; Hashmi, Shahrukh K; Kharfan-Dabaja, Mohamed A; Kindwall-Keller, Tamila; Kröger, Nicolaus; Lazarus, Hillard M; Liesveld, Jane L; Litzow, Mark R; Marks, David I; Nathan, Sunita; Nishihori, Taiga; Olsson, Richard F; Pawarode, Attaphol; Rowe, Jacob M; Savani, Bipin N; Savoie, Mary Lynn; Seo, Sachiko; Solh, Melhem; Tamari, Roni; Verdonck, Leo F; Yared, Jean A; Alyea, Edwin; Popat, Uday; Sobecks, Ronald; Scott, Bart L; Nakamura, Ryotaro; Mesa, Ruben; Saber, Wael.
in: BLOOD ADV, Jahrgang 4, Nr. 9, 12.05.2020, S. 1965-1973.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Survival following allogeneic transplant in patients with myelofibrosis
AU - Gowin, Krisstina
AU - Ballen, Karen
AU - Ahn, Kwang Woo
AU - Hu, Zhen-Huan
AU - Ali, Haris
AU - Arcasoy, Murat O
AU - Devlin, Rebecca
AU - Coakley, Maria
AU - Gerds, Aaron T
AU - Green, Michael
AU - Gupta, Vikas
AU - Hobbs, Gabriela
AU - Jain, Tania
AU - Kandarpa, Malathi
AU - Komrokji, Rami
AU - Kuykendall, Andrew T
AU - Luber, Kierstin
AU - Masarova, Lucia
AU - Michaelis, Laura C
AU - Patches, Sarah
AU - Pariser, Ashley C
AU - Rampal, Raajit
AU - Stein, Brady
AU - Talpaz, Moshe
AU - Verstovsek, Srdan
AU - Wadleigh, Martha
AU - Agrawal, Vaibhav
AU - Aljurf, Mahmoud
AU - Angel Diaz, Miguel
AU - Avalos, Belinda R
AU - Bacher, Ulrike
AU - Bashey, Asad
AU - Beitinjaneh, Amer M
AU - Cerny, Jan
AU - Chhabra, Saurabh
AU - Copelan, Edward
AU - Cutler, Corey S
AU - DeFilipp, Zachariah
AU - Gadalla, Shahinaz M
AU - Ganguly, Siddhartha
AU - Grunwald, Michael R
AU - Hashmi, Shahrukh K
AU - Kharfan-Dabaja, Mohamed A
AU - Kindwall-Keller, Tamila
AU - Kröger, Nicolaus
AU - Lazarus, Hillard M
AU - Liesveld, Jane L
AU - Litzow, Mark R
AU - Marks, David I
AU - Nathan, Sunita
AU - Nishihori, Taiga
AU - Olsson, Richard F
AU - Pawarode, Attaphol
AU - Rowe, Jacob M
AU - Savani, Bipin N
AU - Savoie, Mary Lynn
AU - Seo, Sachiko
AU - Solh, Melhem
AU - Tamari, Roni
AU - Verdonck, Leo F
AU - Yared, Jean A
AU - Alyea, Edwin
AU - Popat, Uday
AU - Sobecks, Ronald
AU - Scott, Bart L
AU - Nakamura, Ryotaro
AU - Mesa, Ruben
AU - Saber, Wael
N1 - © 2020 by The American Society of Hematology.
PY - 2020/5/12
Y1 - 2020/5/12
N2 - Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
AB - Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
U2 - 10.1182/bloodadvances.2019001084
DO - 10.1182/bloodadvances.2019001084
M3 - SCORING: Journal article
C2 - 32384540
VL - 4
SP - 1965
EP - 1973
JO - BLOOD ADV
JF - BLOOD ADV
SN - 2473-9529
IS - 9
ER -